Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abdominal Solid Organ TransplantationMedical Disease After Abdominal Solid Organ Transplantation and the Risk of Solid and Hematologic Malignant Tumor After Transplantation

Abdominal Solid Organ Transplantation: Medical Disease After Abdominal Solid Organ... [Solid organ transplantation is the treatment of choice for selected patients with end-stage organ insufficiency. Currently, the survival of patients after kidney and liver transplantation exceeds respectively 80 and 70% after 5 years, associated in the majority of cases with a good quality of life. While in the early postoperative period the main causes of morbidity and mortality are related to the primary organ dysfunction, surgical complications or postoperative infection, in the long term they are mainly related to the emergence of disorders linked to immunosuppressive therapy side effects or to primary disease recurrence. Monitoring immunosuppressive drug blood levels is a key point in the management of patients after solid organ transplantation in order to minimize the potential adverse effects. However, careful management of potentially modifiable risk factors such as metabolic syndrome, cardiovascular diseases and renal insufficiency may improve long-term survival.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Abdominal Solid Organ TransplantationMedical Disease After Abdominal Solid Organ Transplantation and the Risk of Solid and Hematologic Malignant Tumor After Transplantation

Editors: Pinna, Antonio Daniele; Ercolani, Giorgio
Morelli, Maria Cristina
Abdominal Solid Organ Transplantation — Mar 6, 2015
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/abdominal-solid-organ-transplantation-medical-disease-after-abdominal-y5TdutET0Z

References (35)

Publisher
Springer International Publishing
Copyright
© Springer International Publishing Switzerland 2015
ISBN
978-3-319-16996-5
Pages
83 –94
DOI
10.1007/978-3-319-16997-2_5
Publisher site
See Chapter on Publisher Site

Abstract

[Solid organ transplantation is the treatment of choice for selected patients with end-stage organ insufficiency. Currently, the survival of patients after kidney and liver transplantation exceeds respectively 80 and 70% after 5 years, associated in the majority of cases with a good quality of life. While in the early postoperative period the main causes of morbidity and mortality are related to the primary organ dysfunction, surgical complications or postoperative infection, in the long term they are mainly related to the emergence of disorders linked to immunosuppressive therapy side effects or to primary disease recurrence. Monitoring immunosuppressive drug blood levels is a key point in the management of patients after solid organ transplantation in order to minimize the potential adverse effects. However, careful management of potentially modifiable risk factors such as metabolic syndrome, cardiovascular diseases and renal insufficiency may improve long-term survival.]

Published: Mar 6, 2015

Keywords: Metabolic Syndrome; Liver Transplantation; Chronic Renal Failure; Mycophenolate Mofetil; Calcineurin Inhibitor

There are no references for this article.